IV edaravone-treated patient had longer disease progression milestone-free time for all 6 milestones compared with control. Treatment with intravenous (IV) edaravone was associated with fewer reported ...

There could be new hope for ALS management as a promising drug enters phase 3 clinical trials. ALS is a progressive disease in which the brain loses connection with the muscles, The ALS Association ...

Please provide your email address to receive an email when new articles are posted on . A new analysis of an overall survival study of an investigational immunotherapy platform to treat ALS found it ...

Masitinib is an experimental oral therapy for ALS that's aimed at slowing disease progression. AB Science secured insurance ...

Add Yahoo as a preferred source to see more of our stories on Google. Wheelchair, isolated view Image by Kub The Shadow Simple ManShutterstock A newly published study says that the body’s own immune ...

Amyotrophic lateral sclerosis remains difficult to diagnose and is frequently identified after substantial disease progression, underscoring the need for earlier recognition and expanded therapeutic ...

“[…]we have identified FGF21 as a novel biomarker in ALS that is detected in multiple compartments including muscle, spinal cord, and circulation.” In this ...

Please provide your email address to receive an email when new articles are posted on . The treatment group logged longer times to four disease-progression milestones compared with controls. At 2 ...